Immunopharmacology and Immunotoxicology
Leading citation impact metric from Clarivate Journal Citation Reports
42 papers with at least that number of citations each
State Council for Professorship (HĐGSNN) Scoring
Quyết định số 26/QĐ-HĐGSNN ngày 11/7/2025 (Mục quốc tế)
HĐGSNN Score History
By article publication year| Year | Max Score | Evaluation Details | Source |
|---|---|---|---|
| 2026 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 3.1) | 🔵 Computed |
| 2025 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 3) | 🔵 Computed |
| 2024 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 2.9) | 🔵 Computed |
| 2023 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 3.3) | 🔵 Computed |
| 2022 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 3.712) | 🔵 Computed |
| 2021 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 2.73) | 🔵 Computed |
| 2020 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 2.352) | 🔵 Computed |
| 2019 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 2.086) | 🔵 Computed |
| 2018 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 2.024) | 🔵 Computed |
Note: Domestic journal scores are officially collected from annual HĐGSNN decisions across councils. International journal scores are dynamically computed according to Decision 26/QĐ-HĐGSNN based on quartile and citation metrics in the publication year.
Aims & Scope
The journal Immunopharmacology and Immunotoxicology is devoted to pre-clinical and clinical drug discovery and development targeting the immune system. Research related to the immunoregulatory effects of various compounds, including small-molecule drugs and biologics, on immunocompetent cells and immune responses, as well as the immunotoxicity exerted by xenobiotics and drugs. Only research that describe the mechanisms of specific compounds (not extracts) is of interest to the journal. The journal will prioritise preclinical and clinical studies on immunotherapy of disorders such as chronic inflammation, allergy, autoimmunity, cancer etc. The effects of small-drugs, vaccines and biologics against central immunological targets as well as cell-based therapy, including dendritic cell therapy, T cell adoptive transfer and stem cell therapy, are topics of particular interest. Publications pointing towards potential new drug targets within the immune system or novel technology for immunopharmacological drug development are also welcome. With an immunoscience focus on drug development, immunotherapy and toxicology, the journal will cover areas such as infection, allergy, inflammation, tumor immunology, degenerative disorders, immunodeficiencies, neurology, atherosclerosis and more. Immunopharmacology and Immunotoxicology will accept original manuscripts, brief communications, commentaries, mini-reviews, reviews, clinical trials and clinical cases, on the condition that the results reported are based on original, clinical, or basic research that has not been published elsewhere in any journal in any language (except in abstract form relating to paper communicated to scientific meetings and symposiums).
SCImago & Scopus Journal Intelligence
Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact
Weighted prestige citation metric per document indexed in the Scopus database.
Measures cumulative publication volume and citation impact.
Average citations received per document published in the 2-year window.
Estimated Article Processing Charge for Open Access publication.
Scopus 3-Year Publication & Citation Window
Aggregated from Scopus database across the 3-year SJR evaluation window.
Societal Impact & Inclusivity (SCImago)
Citations in government and international policy documents
Percentage of female authors published in the journal
Real-world societal policy reach and author gender diversity tracked by SCImago.
Scopus Subject Categories
Chinese Academy of Sciences (CAS) Classification
Major / minor zone classification and CAS Early Warning List history
Publishing & Editorial Information
Detailed publisher, peer-review turnaround, and publication cycle specifications
WoS Categories & Quartiles
Detailed JCR / JCI category rankings and quartile breakdown from Clarivate
| Category | Index | Rank | Quartile |
|---|---|---|---|
IMMUNOLOGY | JCRSCIE | 108/183 | Q3 |
PHARMACOLOGY & PHARMACY | JCRSCIE | 163/356 | Q2 |
TOXICOLOGY | JCRSCIE | 52/106 | Q2 |
IMMUNOLOGY | JCISCIE | 68/183 | Q2 |
PHARMACOLOGY & PHARMACY | JCISCIE | 113/356 | Q2 |
TOXICOLOGY | JCISCIE | 39/106 | Q2 |
Annual Historical Statistics & Publications
Track annual publication volume, total citations, and Impact Factor evolution
| Year | Impact Factor | Articles / Year | Total Citations |
|---|---|---|---|
| 2026 | — | 75 | 21 |
| 2025 | 3 | 83 | 191 |
| 2024 | 2.9 | 78 | 379 |
| 2023 | 3.3 | 64 | 525 |
| 2022 | 3.712 | 140 | 1,565 |
| 2021 | 2.73 | 94 | 1,818 |
| 2020 | 2.352 | 78 | 1,414 |
| 2019 | 2.086 | 79 | 1,558 |
| 2018 | 2.024 | 60 | 1,782 |
| 2017 | — | 54 | 1,108 |
| 2016 | — | 56 | 1,332 |
| 2015 | — | 65 | 1,763 |
Journal Metrics & Citation Visualizations
Impact Factor Trend (2018–2024)
Clarivate IF trend for Immunopharmacology and Immunotoxicology
Total Cites vs Self-Cites
Evaluation of scholarly independence and citation reach
Citations per Document
Citation metric windows across 2, 3, and 4 years
Similar Journals in Discipline
Journals in the same research field with comparable impact metrics